Evidence map›Paper›PMID 36959814›Full record

ArticleThe Southern African journal of critical care : the official journal of the Critical Care Society2019

Artesunate compared with quinine for the treatment of severe malaria in adult patients managed in an intensive care unit: A retrospective observational study.

R M Mathiba, L R Mathivha, G D Nethathe

Open access · diamondAbstract read
In one paragraph

Article in The Southern African journal of critical care : the official journal of the Critical Care Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Quinine - a time for re-evaluation?The Southern African journal of critical care : the official journal of the Critical Care Society · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

R M MathibaDepartment of Internal Medicine, Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.
L R MathivhaDepartment of Intensive Care, Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.
G D NethatheDivision of Critical Care, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-6875-8422
University of the Witwatersrand · ZAChris Hani Baragwanath Hospital · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There are limited South African data on the outcomes of patients with severe malaria treated with quinine compared with those treated with artesunate in the intensive care unit (ICU). Objectives: To compare the outcomes of adult patients treated with artesunate against those treated with quinine in the ICU. Primary outcome variables are length of stay (LOS) in the ICU and mortality. Secondary outcomes include the incidence of hypoglycaemic episodes and neurological outcomes. Methods: This was a retrospective cohort study of patients with severe malaria treated at a multidisciplinary ICU with artesunate or quinine from 1 January 2008 to 31 December 2012. Results: Of the 92 patients included in the study, 63 (69.2%) were male. The mean age in the quinine and artesunate groups was 36.2 years and 40.5 years, respectively (p=0.071). Most (98.6%) of the patients with a positive travel history had visited a malaria-endemic region. Of the 53 patients tested for HIV infection, 71.7% tested positive (p=0.520). The average CD4+ cell count of HIV-positive patients treated with quinine was 200 cells/µL compared with 217.17 cells/µL for those treated with artesunate (p=0.875). The mean APACHE II score at admission was 20.85 and 19.62 in the quinine group and artesunate group, respectively (p=0.380). The median LOS was 5 days (range 1 - 27). Mortality was 15.4% in the quinine group and 7.7% in the artesunate group (p=0.246). Conclusion: A statistically insignificant mortality difference was observed in outcomes of the two treatment groups in this retrospective, single-centre cohort study. Contributions of the study: Intravenous artesunate is currently the preferred treatment in the management of patients with severe malaria. However, there are limited local data on the outcomes of artesunate v. quinine therapy for the management of severe malaria in highly monitored clinical environments in non-endemic regions of South Africa.We describe clinical characteristics, management and outcomes of patients with severe malaria treated with quinine and those treated with artesunate in the ICU in a non-endemic region.

Indexed as

Antimalarialscritical illnessICUimported infectionssevere malaria

Identifiers

PMID36959814
PMCPMC10029740
OpenAlexW2969342367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.